panitumumab

Generic Name: panitumumab

Brand Names: Vectibix

Drug Type: Biotech

CAS Number: 339177-26-3

Unique Ingredient Identifier: 6A901E312A

Background: Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.

Panitumumab was granted FDA approval on 27 September 2006.

Indication: 美国FDA批准：用于野生型KRAS(外显子2)转移性结直肠癌(mCRC)患者的一线治疗。

Associated Conditions: Metastatic Colorectal Cancer (CRC)

Clinical Trials

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase 1

Recruiting

Conditions: Advanced Solid Tumors
Kirsten Rat Sarcoma (KRAS) pG12C Mutation

Interventions: Drug: Sotorasib
Drug: RMC-4630
Drug: Afatinib
Drug: MVASI® (bevacizumab-awwb)
Drug: Atezolizumab
Drug: BI 1701963
Drug: AMG 404
Drug: TNO155
Drug: Trametinib
Drug: Pembrolizumab
Drug: Palbociclib
Drug: Everolimus
Drug: IV Chemotherapy (Regimen 1)
Drug: Carboplatin, pemetrexed, docetaxel, paclitaxel
Drug: Panitumumab
Drug: IV Chemotherapy (Regimen 2)

First Posted Date: 2019-12-04

Last Posted Date: 2025-03-27

Lead Sponsor: Amgen

Target Recruit Count: 1200

Registration Number: NCT04185883

Locations: 🇺🇸
Arizona Oncology Associates Professional Corporation, Tucson, Arizona, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States

and more 87 locations

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: BRAF V600E Negative
Metastatic Colorectal Adenocarcinoma
NRAS Gene Mutation Negative
KRAS Gene Mutation Negative
Stage IVA Colorectal Cancer AJCC v8
Stage IVB Colorectal Cancer AJCC v8
Stage IVC Colorectal Cancer AJCC v8
Locally Advanced Unresectable Colorectal Adenocarcinoma
Stage III Colorectal Cancer AJCC v8
Stage IIIB Colorectal Cancer AJCC v8

Interventions: Biological: Cetuximab
Drug: Regorafenib
Drug: Irinotecan
Biological: Panitumumab

First Posted Date: 2019-10-07

Last Posted Date: 2024-02-07

Lead Sponsor: Academic and Community Cancer Research United

Target Recruit Count: 22

Registration Number: NCT04117945

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States

and more 12 locations

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

Phase 2

Not yet recruiting

Conditions: Treatment Related Cancer

Interventions: Drug: Panitumumab
Drug: Irinotecan
Drug: Folinic acid
Drug: 5-FU

First Posted Date: 2019-07-26

Last Posted Date: 2019-07-26

Lead Sponsor: Ludwig-Maximilians - University of Munich

Target Recruit Count: 120

Registration Number: NCT04034173

Locations: 🇩🇪
Ludwigs Maximialians University, Munich, Germany

Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: Advanced Microsatellite Stable Colorectal Carcinoma
RAS Wild Type
Microsatellite Stable
MSI-H Colorectal Cancer
Metastatic Microsatellite Stable Colorectal Carcinoma
Stage IV Colorectal Cancer AJCC v8

Interventions: Drug: Niraparib
Biological: Panitumumab

First Posted Date: 2019-06-12

Last Posted Date: 2025-04-09

Lead Sponsor: Emory University

Target Recruit Count: 26

Registration Number: NCT03983993

Locations: 🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States

Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR

Phase 2

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Panitumumab

First Posted Date: 2019-05-07

Last Posted Date: 2022-04-06

Lead Sponsor: King Abdullah Medical City

Target Recruit Count: 30

Registration Number: NCT03940131

Locations: 🇸🇦
King Abdullah Medical City, Holy Capital, Mecca, Makkah Western, Saudi Arabia

Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal

Phase 2

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Panitumumab
Drug: Irinotecan
Drug: Folinic acid
Drug: 5-FU

First Posted Date: 2018-11-23

Last Posted Date: 2021-06-30

Lead Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo

Target Recruit Count: 31

Registration Number: NCT03751176

Locations: 🇪🇸
ICO Girona Dr. Josep Trueta, Gerona, Barcelona, Spain
🇪🇸
Hospital de Granollers, Granollers, Barcelona, Spain
🇪🇸
Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain

and more 15 locations

Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer

Phase 3

Active, not recruiting

Conditions: Colorectal Cancer

Interventions: Drug: FOLFOX regimen
Drug: Panitumumab
Drug: Bevacizumab
Drug: FOLFIRI regimen

First Posted Date: 2018-08-17

Last Posted Date: 2024-10-21

Lead Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Target Recruit Count: 419

Registration Number: NCT03635021

Locations: 🇪🇸
Spanish Cooperative Group for the Treatment of Digestive Tumors, Madrid, Spain

Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

Phase 1

Recruiting

Conditions: Malignant Brain Neoplasm
Malignant Glioma

Interventions: Procedure: Near-Infrared Fluorescence Imaging
Biological: Panitumumab
Drug: Panitumumab-IRDye800
Device: POINPOINT-IR9000

First Posted Date: 2018-04-27

Last Posted Date: 2025-02-12

Lead Sponsor: Eben Rosenthal

Target Recruit Count: 46

Registration Number: NCT03510208

Locations: 🇺🇸
Stanford University School of Medicine, Palo Alto, California, United States

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Phase 2

Completed

Conditions: Colon Cancer

Interventions: Drug: Panitumumab
Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2018-02-22

Last Posted Date: 2025-04-13

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 56

Registration Number: NCT03442569

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 2 locations

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Phase 1

Recruiting

Conditions: Pancreatic Adenocarcinoma

Interventions: Procedure: Fluorescence Imaging
Biological: Panitumumab
Drug: Panitumumab-IRDye800

First Posted Date: 2017-12-27

Last Posted Date: 2025-02-17

Lead Sponsor: Eben Rosenthal

Target Recruit Count: 27

Registration Number: NCT03384238

Locations: 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy